![Biomedicines | Free Full-Text | Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat Biomedicines | Free Full-Text | Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat](https://pub.mdpi-res.com/biomedicines/biomedicines-09-00313/article_deploy/html/images/biomedicines-09-00313-ag.png?1617783328)
Biomedicines | Free Full-Text | Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
![Structures of the boosters (CYP inhibitors) ritonavir and cobicistat,... | Download Scientific Diagram Structures of the boosters (CYP inhibitors) ritonavir and cobicistat,... | Download Scientific Diagram](https://www.researchgate.net/publication/338343436/figure/fig4/AS:842933066555398@1577982312337/Structures-of-the-boosters-CYP-inhibitors-ritonavir-and-cobicistat-and-selected.png)
Structures of the boosters (CYP inhibitors) ritonavir and cobicistat,... | Download Scientific Diagram
![HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor‐Dependent Increases in NADPH Oxidase 1 (Nox1), C‐C Chemokine Receptor Type 5 (CCR5), and Inflammation | Journal HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor‐Dependent Increases in NADPH Oxidase 1 (Nox1), C‐C Chemokine Receptor Type 5 (CCR5), and Inflammation | Journal](https://www.ahajournals.org/cms/asset/d9b9ed03-620a-4999-938a-478bf7b161e6/jah35534-fig-0007.png)
HIV Protease Inhibitor Ritonavir Impairs Endothelial Function Via Reduction in Adipose Mass and Endothelial Leptin Receptor‐Dependent Increases in NADPH Oxidase 1 (Nox1), C‐C Chemokine Receptor Type 5 (CCR5), and Inflammation | Journal
![PDF] Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. | Semantic Scholar PDF] Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7d953a0329d21331a2a46a14d7aafc1acda29ab6/2-Table1-1.png)
PDF] Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients. | Semantic Scholar
![Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study - The Lancet HIV Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study - The Lancet HIV](https://www.thelancet.com/cms/attachment/b672c9a6-b901-40c7-adc8-d4ab4380d4c9/gr1_lrg.jpg)
Lopinavir–ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir–ritonavir without rifampicin: a pharmacokinetic modelling and clinical study - The Lancet HIV
![VisualAbstract: Dolutegravir noninferior to a ritonavir-boosted protease inhibitor regimen for treating HIV | 2 Minute Medicine VisualAbstract: Dolutegravir noninferior to a ritonavir-boosted protease inhibitor regimen for treating HIV | 2 Minute Medicine](https://www.2minutemedicine.com/wp-content/uploads/2023/07/2MM_07.16.2023_1_Alisha_Dolutegravir.jpg)
VisualAbstract: Dolutegravir noninferior to a ritonavir-boosted protease inhibitor regimen for treating HIV | 2 Minute Medicine
![The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins - ScienceDirect The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0753332223004249-gr1.jpg)
The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins - ScienceDirect
![Implications of the Digestion of Milk-Based Formulations for the Solubilization of Lopinavir/Ritonavir in a Combination Therapy | Molecular Pharmaceutics Implications of the Digestion of Milk-Based Formulations for the Solubilization of Lopinavir/Ritonavir in a Combination Therapy | Molecular Pharmaceutics](https://pubs.acs.org/cms/10.1021/acs.molpharmaceut.3c00072/asset/images/large/mp3c00072_0006.jpeg)